Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Igarashi, T.
Right arrow Articles by Ito, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igarashi, T.
Right arrow Articles by Ito, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 31:13-17 (2001)
© 2001 Foundation for Promotion of Cancer Research

Serum Immunosuppressive Acidic Protein as a Potent Prognostic Factor for Patients with Metastatic Renal Cell Carcinoma

Tatsuo Igarashi1, Toyofusa Tobe1, Hiroaki Kuramochi1, Koichiro Akakura1, Tomohiko Ichikawa1, Satoshi Hamano2, Noriyuki Suzuki2, Yuzo Furuya3 and Haruo Ito1,+

1Department of Urology, Chiba University School of Medicine and 2Department of Urology, Asahi General Hospital, 3Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Chiba, Japan

Background: Estimation of survival probability of individual patients with metastatic renal cell carcinoma was difficult owing to diverse prognostic factors. We analyzed serum immunosuppressive acidic protein (IAP) levels and the cutoff value, then tested its validity for assessing patients’ prognoses.

Methods: Serum IAP was measured longitudinally in 84 patients with metastatic disease. Before therapy, cutoff levels of IAP were tested every 20 µg/ml between 600 and 1200 µg/ml. The prognostic importance of IAP and its cutoff level was estimated.

Results: The cutoff level of IAP was set at 800 µg/ml for 40 patients who had metastatic disease with the primary tumor in situ and for 44 patients with recurrent disease. IAP was found to be a significant prognostic factor for both patient groups.

Conclusions: Serum IAP is an important prognostic factor for patients with metastatic renal cell carcinoma. Stratification of patients according to prognosis is feasible using the cutoff level.

+ For reprints and all correspondence: Tatsuo Igarashi, Department of Urology, 1–8–1, Inohana, Chuo-ku, Chiba 260-8670, Japan E-mail: tigaras@med.m.chiba-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.